International S.c.a. Artal - 10 May 2024 Form 4 Insider Report for LEXICON PHARMACEUTICALS, INC. (LXRX)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
14 May 2024, 17:17:40 UTC
Prior SEC filing
25 Mar 2024
Next SEC filing
07 Jun 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
ARTAL INTERNATIONAL S.C.A., By: Artal International Management S.A., its managing partner, By: /s/ Pierre Claudel, Name: Pierre Claudel, Title: Managing Director

Key filing fact

International S.c.a. Artal filed Form 4 for LEXICON PHARMACEUTICALS, INC. (LXRX) on 14 May 2024.

Key facts

  • This page summarizes International S.c.a. Artal's Form 4 filing for LEXICON PHARMACEUTICALS, INC. (LXRX).
  • 3 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 14 May 2024, 17:17.

Change

  • Previous filing in this sequence was filed on 25 Mar 2024.
  • Current net transaction value: +$124,875,037.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LXRX transaction

Common Stock

Options Exercise

Transaction value
Shares
+57,546,100
Change %
+73%
Price
Shares after
136,180,481
Date
10 May 2024
Ownership
See Footnotes
Footnotes
F1, F2, F5, F6
LXRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
3,516,214
Date
10 May 2024
Ownership
See Footnotes
Footnotes
F3, F5, F6
LXRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
35,402,689
Date
10 May 2024
Ownership
See Footnotes
Footnotes
F4, F5, F6

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LXRX transaction Derivative

Series A Convertible Preferred Stock

Award

Transaction value
$124,875,037
Shares
+1,150,922
Change %
Price
$108.50*
Shares after
1,150,922
Date
10 May 2024
Ownership
See Footnotes
Underlying class
Common Stock
Underlying amount
57,546,100
Exercise price
Footnotes
F1, F2, F5, F6
LXRX transaction Derivative

Series A Convertible Preferred Stock

Options Exercise

Transaction value
$0
Shares
-1,150,922
Change %
-100%
Price
$0.000000*
Shares after
0
Date
10 May 2024
Ownership
See Footnotes
Underlying class
Common Stock
Underlying amount
57,546,100
Exercise price
Footnotes
F1, F2, F5, F6
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

On March 13, 2024, Artal International S.C.A. acquired 1,150,922 shares of Series A convertible preferred stock, $0.01 par value per share (the "Preferred Stock") of the Issuer at a price of $108.50 per share. Each share of Preferred Stock would automatically convert into 50 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock") upon receipt of shareholder approval and the satisfaction of certain other conditions (the "Conditions"); however, absent the satisfaction of such conditions, the shares were not convertible and as such, the Preferred Stock was originally reported on Table I. On May 10, 2024, all Conditions were met, and the 1,150,922 shares of Preferred Stock became derivative securities and automatically converted into 57,546,100 shares of Issuer Common Stock.

Footnote F2

These securities are directly held by Artal International S.C.A.

Footnote F3

These securities are directly held by Invus Public Equities, L.P.

Footnote F4

These securities are directly held by Invus, L.P.

Footnote F5

Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. The Geneva branch of Artal International S.C.A. is the managing member of Invus Public Equities Advisors, LLC. Artal International S.C.A. is the managing member of Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A. The sole stockholder of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the "Stichting"). Mr. Amaury Wittouck is the sole member of the board of the Stichting.

Footnote F6

Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

SEC remarks

Invus US Partners LLC directly holds 5,451,204 shares of Common Stock, which securities are reported on a separate Form 4. For purposes of Section 16 of the Exchange Act, the Reporting Persons may be deemed to be directors by deputization of the Issuer by virtue of Invus, L.P.'s right to designate certain members of the Issuer's board of directors pursuant to a stockholders' agreement between the Issuer and Invus, L.P.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .